

A Designer Bleomycin with Significantly Improved DNA Cleavage Activity

Sheng-Xiong Huang,^{†,‡,§} Zhiyang Feng,^{||,¶} Liyan Wang,^{||,¶} Ute Galm,^{||} Evelyn Wendt-Pienkowski,^{||} Dong Yang,[†] Meifeng Tao,^{||} Jane M Coughlin,^{||} Yanwen Duan,^{*,‡} and Ben Shen^{*,†,‡,§,||}


[†]Department of Chemistry, [‡]Department of Molecular Therapeutics, and [§]Natural Products Library Initiative at The Scripps Research Institute, The Scripps Research Institute, Jupiter, Florida 33458, United States

^{||}Division of Pharmaceutical Sciences, University of Wisconsin—Madison, Madison, Wisconsin 53705, United States

[‡]Hunan Engineering Research Center of Combinatorial Biosynthesis and Natural Product Drug Discovery, Changsha, Hunan 410329, China

Supporting Information

ABSTRACT: The bleomycins (BLMs) are used clinically in combination with a number of other agents for the treatment of several types of tumors, and the BLM, etoposide, and cisplatin treatment regimen cures 90–95% of metastatic testicular cancer patients. BLM-induced pneumonitis is the most feared, dose-limiting side effect of BLM in chemotherapy, which can progress into lung fibrosis and affect up to 46% of the total patient population. There have been continued efforts to develop new BLM analogues in the search for anticancer drugs with better clinical efficacy and lower lung toxicity. We have previously cloned and characterized the biosynthetic gene clusters for BLMs from *Streptomyces verticillus* ATCC15003, tallysomycins from *Streptoalloteichus hindustanus* E465-94 ATCC31158, and zorbamycin (ZBM) from *Streptomyces flavoviridis* SB9001. Comparative analysis of the three biosynthetic machineries provided the molecular basis for the formulation of hypotheses to engineer novel analogues. We now report engineered production of three new analogues, 6'-hydroxy-ZBM, BLM Z, and 6'-deoxy-BLM Z and the evaluation of their DNA cleavage activities as a measurement for their potential anticancer activity. Our findings unveiled: (i) the disaccharide moiety plays an important role in the DNA cleavage activity of BLMs and ZBMs, (ii) the ZBM disaccharide significantly enhances the potency of BLM, and (iii) 6'-deoxy-BLM Z represents the most potent BLM analogue known to date. The fact that 6'-deoxy-BLM Z can be produced in reasonable quantities by microbial fermentation should greatly facilitate follow-up mechanistic and preclinical studies to potentially advance this analogue into a clinical drug.



INTRODUCTION

The bleomycins (BLMs), a family of glycopeptide-derived antibiotics produced by several *Streptomyces* species, are used clinically in combination with a number of other agents for the treatment of several types of tumors, notably germ cell tumors, squamous cell carcinomas, and malignant lymphomas.^{1–4} The combination BLM, etoposide and cisplatin treatment regimen cures 90–95% of metastatic testicular cancer patients, clearly representing a therapeutic success story.^{5,6} Almost uniquely among anticancer drugs, BLM exhibits low myelo- and immunosuppression, promoting its wide application in combination chemotherapy.^{1–4} However, BLM-induced pneumonitis is the most feared, dose-limiting side effect of BLM in chemotherapy, which can progress into lung fibrosis and affect up to 46% of the total patient population.^{3,5–7} Central to the development of BLM-induced pneumonitis is endothelial damage of lung vasculature due to BLM-induced cytokines and free radicals, and the resulting lung toxicity has been proposed to be independent of the cytotoxicity of BLMs to tumor cells.^{3,7}

BLMs are thought to exert their biological effects through a sequence selective, metal-dependent oxidative cleavage of double stranded DNA in the presence of oxygen.^{2–4} The BLMs can be dissected into four functional domains (Figure 1). The pyrimidoblastic acid subunit along with the adjacent β-hydroxyl histidine constitutes the metal-binding domain for Fe²⁺ complexation and molecular oxygen activation responsible for DNA cleavage. The bithiazole and C-terminal amine moiety provide the majority of the BLM-DNA affinity and may contribute to polynucleotide recognition and the DNA cleavage selectivity. The (2S, 3S, 4R)-4-amino-3-hydroxy-2-methylpentanoic acid subunit provides the linker between the metal-binding and DNA-binding sites and plays an important role in the efficiency of DNA cleavage by BLMs. The disaccharide moiety has been speculated to participate in cell recognition by BLMs and possibly in cellular uptake and metal ion coordination. Consequently, there have been extraordinary

Received: June 11, 2012

Published: July 25, 2012




Figure 1. Structures of selected members of the bleomycin (BLM) family of antitumor antibiotics: BLM A2, BLM B2, tallsomycin (TLM) S₁₀B, phleomycin (PLM) D1, and zorbamycin (ZBM), as well as the engineered ZBM analogue, 6'-hydroxy-ZBM, and BLM analogues, BLM Z and 6'-deoxy-BLM Z. See Figures S3 and S6 for the numberings of ZBMs and BLMs, respectively.

efforts to develop new BLM analogues by both organic synthesis^{1–3,8–10} and directed biosynthesis^{11,12} in the search for anticancer drugs with better clinical efficacy and lower lung toxicity. Numerous BLM analogues have been prepared in the past three decades, helping to define the fundamental functional roles of the individual domains, and thereby lending support to the premise that DNA damage is the major contributor to the cytotoxicity of BLMs to tumor cells.^{1–3,8–12} However, it can be argued that none of these analogues have

improved therapeutic properties, and tinkering at any position within the metal-binding domain, the linker region, or the bithiazole moiety severely reduced the ability of the drugs to mediate DNA cleavage. In contrast, the disaccharide moiety remains largely unexplored, mainly due to the lack of BLM analogues prepared with varying sugars, although it is known that deglyco-BLMs are much less effective at mediating DNA cleavage.^{1–3,8,9}

The naturally occurring BLMs differ structurally primarily at the C-terminus of the hybrid peptide-polyketide aglycones of the glycopeptides. The commercial product, Bleomoxane, contains BLM A2 and BLM B2 as the principle constituents (Figure 1).

Structurally related to the BLMs are the tallsomycins (TLMs), phleomycins (PLMs), and zorbamycin (ZBM).^{2,12,13} One characteristic structural difference among these compounds is the presence of a bithiazole unit in the BLM and TLM aglycones and a thiazolylthiazole unit in the PLM and ZBM aglycones. In addition, while BLMs, PLMs, and TLMs share the same disaccharide moiety and many of the same terminal amine moieties, TLMs feature an additional sugar moiety and ZBM has its unique disaccharide and terminal amine moiety (Figure 1). The PLMs, TLMs, and ZBM exert their biological effect through the same oxidative DNA cleavage mechanism as the BLMs.^{2–4} Although the BLMs are the only members of this family that have been developed into clinical drugs, the PLMs and ZBM are significantly more potent than the BLMs in mediating DNA cleavage. This raises the question what is the structure and activity relationship of PLMs and ZBM in comparison with the BLMs and can the superior DNA cleavage activity associated with the PLMs and ZBM be engineered into new BLM analogues and exploited for anticancer drug discovery.

Complementary to chemical synthesis, combinatorial biosynthesis—the generation of novel analogues of natural products by genetic engineering of biosynthetic pathways—offers a promising alternative to preparing microbial metabolites and their analogues biosynthetically.^{12,14} Specific structural alterations in the presence of abundant functional groups can often be achieved by precise rational manipulation of the biosynthetic machinery. A minimum of four requirements must be met before combinatorial biosynthesis can be successfully exploited to generate structural diversity of natural products: (i) availability of the gene clusters encoding the production of a particular natural product or a family of natural products, (ii) genetic and biochemical characterizations of the biosynthetic machinery for the targeted natural products to a degree that the combinatorial biosynthesis principles can be rationally applied to engineer the designer analogues, (iii) expedient genetic systems for in vivo manipulation of genes governing the production of the target molecules in their native producers or heterologous hosts, and (iv) production of the natural products or their engineered analogues to levels that are appropriate for detection, isolation, and structural and biological characterizations.

We have previously cloned, sequenced and characterized the biosynthetic gene clusters for BLMs from *Streptomyces verticillus* ATCC15003,^{15–21} TLMs from *Streptoalloteichus hindustanus* E465-94 ATCC31158,^{22–24} and ZBM from *Streptomyces flavoviridis* SB9001,²⁵ a ZBM-overproducer derived from the wild-type *S. flavoviridis* ATCC21892 strain¹³ (Figure S1). Comparative analysis of the three biosynthetic gene clusters and pathways provided the molecular basis on which to

formulate hypotheses for engineering novel analogues.¹² We postulate that (i) the assembly of the hybrid peptide–polyketide aglycones is catalyzed by the hybrid nonribosomal peptide synthetase (NRPS)–polyketide synthase (PKS) megasynthases, in which domain variations can account for the major structural differences among the BLM, TLM, and ZBM aglycones; (ii) in contrast to this, the seemingly identical domain organization of the NRPS modules responsible for the heterocycle formation, produces the distinct structural entities bithiazole and thiazolinythiazole, for BLM/TLM and ZBM, respectively; and (iii) variations in sugar biosynthesis and glycosylation dictate the final BLM, TLM, and ZBM glycopeptide scaffolds (Figure S2). The feasibility of engineering the biosynthesis of BLM, TLM, and ZBM in their native producers has also been demonstrated by the generation of the $\Delta blmD$ mutant strain *S. verticillus* SBS, which produces decarbamoyl-BLM,²¹ the $\Delta tlmH$ mutant strain *S. hindustanus* SB8005, which produces des-talose TLM,²⁴ and the numerous mutant strains of *S. flavoviridis*, which help define the precise boundaries of the ZBM gene cluster.^{12,25} However, in vivo manipulations in *S. verticillus* and *S. hindustanus* remain inefficient, despite great effort, precluding their practical use as a preferred host in which to engineer novel BLM analogues. Although an expedient genetic system has been developed for *S. flavoviridis*, the molecular mechanism differentiating bithiazole biosynthesis in BLM and TLM from thiazolinythiazole biosynthesis in ZBM remains unknown, and consequently, manipulation of the ZBM biosynthetic machinery for the production of analogues containing the characteristic BLM bithiazole moiety, in the BLM aglycone, has not been successful.^{12,25} One way to circumvent both problems is to produce novel BLM analogues by engineering the BLM biosynthetic machinery in *S. flavoviridis*.

Here we report the engineered production of a ZBM analogue, 6'-hydroxy-ZBM, containing the BLM disaccharide and two BLM analogues, BLM Z and 6'-deoxy-BLM Z, having the ZBM terminal amine moiety and the BLM or ZBM disaccharide, respectively, all in *S. flavoviridis*. We also evaluated the engineered ZBM and BLM analogues, in comparison with ZBM and BLM A2 as controls, as to their DNA cleavage activities as a measurement for their potential anticancer activity. Our findings unveiled: (i) the disaccharide moiety plays an important role in the DNA cleavage activity of BLMs and ZBM, (ii) the ZBM disaccharide significantly enhances the potency of BLM, and (iii) 6'-deoxy-BLM Z represents the most potent BLM analogue known to date. The fact that 6'-deoxy-BLM Z is biosynthesized by a recombinant strain and can be produced in reasonable quantities by scale-up microbial fermentation should alleviate the concern for its availability, thereby setting the stage to carry out the mechanistic and preclinical studies needed to potentially advance this analogue into a clinical drug.

METHODS

The *S. flavoviridis* recombinant strain SB9013, which produces 6'-hydroxy-ZBM, was constructed from the *S. flavoviridis* $\Delta zbmL$ mutant strain SB9003²⁵ by cross-complementation of the $\Delta zbmL$ mutation with *blmG*. The *S. flavoviridis* recombinant strain SB2026, which produces BLM Z and 6'-deoxy-BLM Z, was constructed from the *S. flavoviridis* $\Delta zbmVIII$ mutant strain SB9025 by expression of the BLM gene cluster introduced on pBS54, the bacterial artificial chromosome (BAC)-based vector containing the entire BLM cluster. The structures of 6'-hydroxy-ZBM, BLM Z, and 6'-deoxy-BLM Z were elucidated by a combination of mass spectrometry (MS) and ¹H and ¹³C NMR

spectroscopic analyses, as well as by comparison to the ¹H and ¹³C NMR data of BLM A2^{21,23,24} and ZBM.¹³ The DNA cleavage activities of 6'-hydroxy-ZBM, BLM Z, and 6'-deoxy-BLM Z were determined in plasmid relaxation assays with pBluescript II SK(+) in comparison with BLM A2 and ZBM.^{9,21,23} A complete description of materials, methods, and detailed experimental procedures, as well as tables and figures, is available as Supporting Information (SI).

RESULTS

Engineering the *S. flavoviridis* Recombinant Strain SB9013 That Produces 6'-Hydroxy-ZBM. We previously constructed the *S. flavoviridis* $\Delta zbmL$ mutant strain SB9003, in which ZBM production was abolished (Figure 2B, panels I and II). Introduction of a complementation construct, pBS9019, in which the expression of *zbmL* is under the control of the constitutive promoter *Erme**, into SB9003 afforded a recombinant strain SB9009, whose ZBM production was restored (Figure 2B, panels I, II, and III).^{12,25} These results demonstrate the feasibility of manipulating disaccharide biosynthesis in the ZBM machinery of *S. flavoviridis*.

The $\Delta zbmL$ mutant strain SB9003 is thought to accumulate NDP-D-mannose instead of NDP-4-keto-6-deoxy-D-mannose, the native substrate for the ZbmG epimerase.^{12,25} ZbmG apparently cannot accept NDP-D-mannose as an alternative substrate for catalyzing the analogous epimerization at the C-5' position to afford the corresponding NDP-L-gulose, without which ZBM biosynthesis was apparently abolished (Figure 2A, path b).^{12,25} In contrast, the BlmG epimerase in BLM biosynthesis catalyzes the epimerization of NDP-D-mannose directly into NDP-L-gulose, which is subsequently incorporated into the disaccharide moiety of BLM by the corresponding BlmE and BlmF glycosyltransferases (Figure S2).^{12,16,21,22} Cross-complementation of the $\Delta zbmL$ mutation with constructs containing either *blmG* alone or in combinations with *blmE*, *blmF*, or both, therefore, represents an attractive strategy for engineering a new ZBM analogue carrying the BLM disaccharide (Figure 2A, path a).

Three integrative plasmids, pBS57, pBS61, and pBS63 were constructed, each containing the constitutive *Erme** promoter to control the expression of *blmGF* (pBS57), *blmGEF* (pBS61), or *blmG* (pBS63), respectively (SI). These plasmids were introduced into SB9003 to yield the $\Delta zbmL$ cross-complementation strains SB9011 (SB9003/pBS57), SB9012 (SB9003/pBS61), and SB9013 (SB9003/pBS63) (SI). The recombinant strains SB9011, SB9012, and SB9013, were fermented under conditions described previously,^{13,25} using the *S. flavoviridis* SB9001 and the $\Delta zbmL$ mutant strain SB9003 as controls (SI). HPLC analysis of the metabolites produced showed that ZBM production was not restored and instead, a new metabolite, named 6'-hydroxy-ZBM, with a distinct retention time in comparison to ZBM, was detected in all three cross-complementation strains (Figure 2B, panels IV, V, VI). The titers of 6'-hydroxy-ZBM in SB9011, SB9012, and SB9013 were similar, estimated to be ~4 mg/L (Figure 2B, panels IV, V, VI), in comparison with that for ZBM (~10 mg/L) from the SB9001 strain (Figure 2B, panel I).¹³

A scale-up fermentation of SB9013 was carried out to purify 6'-hydroxy-ZBM for structural elucidation (SI). Briefly, the fermentation broth (30 L) was centrifuged, and the supernatant was collected and adjusted to pH 7.0. After sequential column chromatography on Amberlite IRC-50 and Diaion HP-20, followed by semipreparative HPLC on a C-18 column, the new metabolite was purified as a blue 6'-hydroxy-ZBM•Cu²⁺




Figure 2. Engineered production of 6'-hydroxy-ZBM and evaluation of its DNA cleavage activity in comparison with BLM A2 and ZBM. (A) Proposed pathways for BLM and ZBM sugar biosynthesis in *S. verticillius* and *S. flavoviridis*, respectively, and cross-complementation of the $\Delta zbmL$ mutant strain SB9003 with *blmG* for the production of 6'-hydroxy-ZBM in SB9011, SB9012, and SB9013. (B) HPLC analysis of ZBM (●) production in SB9001, SB9003, and SB9009 and 6'-hydroxy-ZBM (○) production in SB9011, SB9012, and SB9013. (C) DNA cleavage activities of 6'-hydroxy-ZBM as observed in plasmid relaxation assays with pBluescript II SK(+) in comparison with BLM A2 and ZBM. Form I, supercoiled plasmid DNA; form II, open circular plasmid DNA; form III, linearized plasmid DNA; EC₅₀, effective concentration at 50% plasmid DNA relaxation. See Figure S7 for relative ratios of single-strand cleavage (Form II) and double-strand cleavage (Form III) of supercoiled plasmid DNA (Form I).

complex (10 mg). Further treatment of the 6'-hydroxy-ZBM•Cu²⁺ complex with EDTA to remove Cu²⁺, followed by HPLC on a C-18 column, finally afforded Cu²⁺-free 6'-hydroxy-ZBM as a white powder (3.6 mg).

Structural elucidation of 6'-hydroxy-ZBM was first carried out by a combination of MS and ¹H and ¹³C NMR spectroscopic analyses, as well as by comparison of the resultant data with ZBM¹³ and BLM A2^{21,23,24} (SI). Electro-spray ionization (ESI)-MS analysis, in positive mode, of the 6'-hydroxy-ZBM•Cu²⁺ complex afforded an [M + Cu]²⁺ ion at *m/z* 745.5 and of Cu²⁺-free 6'-hydroxy-ZBM afforded two ions, an [M + 2H]²⁺ ion at *m/z* 714.8 and an [M + H + Na]²⁺ ion at *m/z* 725.8. High resolution (HR) matrix-assisted laser desorption ionization (MALDI)-MS analysis, in positive mode, of Cu²⁺-free 6'-hydroxy-ZBM yielded an [M + H]⁺ ion at *m/z* 1428.5634, establishing the molecular formula of 6'-hydroxy-ZBM as C₅₅H₈₅N₁₉O₂₂S₂ (calculated for C₅₅H₈₅N₁₉O₂₂S₂ + H⁺, 1428.5631). The 16 mass unit increase of the new metabolite in comparison with ZBM supported the assignment of the new metabolite as a hydroxylated-ZBM analogue, the hydroxylation regiochemistry of which was assigned on the basis of collision-induced dissociation (CID) tandem MS analysis. The CID tandem MS of the [M + 2H]²⁺ ion at *m/z* 714.8 yielded four diagnostic fragments at *m/z* 1233.2, 1061.2, 612.2, and 531.2, corresponding to the [M - (3-O-carbamoyl-mannose) + H]⁺, [M - (2-O-(3-O-carbamoyl-mannosyl)-gulose) + H]⁺, [M - (3-O-carbamoyl-mannose) + 2H]²⁺, and [M - (2-O-(3-O-carbamoyl-mannosyl)-gulose) + 2H]²⁺ ions, respectively. Taken together, these results suggested that the new metabolite contained the BLM disaccharide 3-O-carbamoyl- α -D-mannosyl-L-gulose (Figure 1), as would be expected from cross-complementation of the $\Delta zbmL$ mutant strain by *blmG* (Figure 2A).

The structure of 6'-hydroxy-ZBM, a new ZBM analogue containing a BLM disaccharide (Figure 1), was finally established on the basis of comprehensive 1D and 2D NMR analysis (SI, Figures S3, S8–S12 and Tables S1, S2). The ¹H and ¹³C NMR spectra of 6'-hydroxy-ZBM are very similar to those of ZBM¹³ except for the disaccharide moiety. The signals for the methyl group [δ_C at 17.3 and δ_H at 0.92 (d, *J* = 8.0 Hz) for C-6' in ZBM] disappeared and instead, signals for the hydroxymethylene group [δ_C at 63.4 and δ_H at 3.58 (m) for C-6' in 6'-hydroxy-ZBM] appeared. The signals for the disaccharide moiety of 6'-hydroxy-ZBM are almost identical to those of BLM A2.^{13,21,23,24} These analyses also enabled the full ¹H and ¹³C NMR spectroscopic assignments of 6'-hydroxy-ZBM as summarized in Tables S1 and S2 (SI).

Engineering the *S. flavoviridis* Recombinant Strain SB9027 That Produces ZBM, 6'-Hydroxy-ZBM, BLM Z, and 6'-Deoxy-BLM Z. We have previously reported a BAC-based strategy for natural product production and engineering in heterologous *Streptomyces* hosts.^{26–29} We adopted the BAC-based strategy to circumvent the technical difficulties encountered in manipulating BLM biosynthesis in its native producer *S. verticillius* by expressing the BLM biosynthetic gene cluster in *S. flavoviridis*, for which an expedient genetic system has been developed and the feasibility of engineering ZBM biosynthesis has been demonstrated.^{12,25}

A BAC library of the BLM-producing *S. verticillius* ATCC15003 strain was constructed according to the published protocol (SI).²⁷ The average insert size of the BAC library was ~80 kb as determined by pulsed-field gel electrophoresis analysis of *Hind*III digests from 36 randomly selected clones.

The *S. verticillus* library (~2000 clones) was screened using DNA fragments flanking the BLM cluster to isolate BAC clones that harbored the intact BLM cluster (SI). Two positive clones, pBS54 and pBS55, were identified, containing a 120-kb and an 80-kb insert, respectively. End-sequencing of both clones confirmed that pBS54 harbored the entire intact BLM cluster (Figure 3B) (SI).

pBS54 was first mobilized into selected model *Streptomyces* hosts,^{27,29} *Streptomyces albus* J1074, *Streptomyces lividans* K4-114, and *Streptomyces coelicolor* M512, via conjugation, affording the corresponding recombinant strains SB9028 (*S. albus* J1074/pBS54), SB9029 (*S. lividans* k4-114/pBS54), and SB9030 (*S. coelicolor* M512/pBS54), respectively. The three recombinant strains were fermented along with *S. verticillus* ATCC15003 as a positive control.¹⁶ BLM production was not detected under any conditions examined (SI and Figure S4).

pBS54 was next mobilized into *S. flavoviridis* SB9001¹³ via conjugation to afford the recombinant strain SB9027. Fermentation of SB9027, with SB9001 as a positive control, was carried out under the optimized conditions for ZBM production¹³ (SI). HPLC analysis of the fermentation showed the production of two new major metabolites, together with several minor metabolites, including ZBM and 6'-hydroxy-ZBM, the structures of which were confirmed by MS analysis and comparison to known standards (Figure 3C, panels I and II) (SI). Production of ZBM and 6'-hydroxy-ZBM in SB9027 indicated that the biosynthetic machineries for both BLM and ZBM disaccharides are functional (Figure 3A).

The two new major products from SB9027 exhibited almost identical UV-vis spectra as BLMs, and both featured absorbance at 248 and 294 nm, which is characteristic for the bithiazole moiety of the BLM aglycone, suggesting that they are most likely BLM analogues.^{13,21,23,24} ESI-MS analysis in positive mode of the two new products yielded $[M + Cu]^{2+}$ ions at m/z 722.3 and 714.4, respectively, which differ from any of the BLMs known to date.^{1-4,8-13,21,24} In an analogy to the structural relationship between ZBM and 6'-hydroxy-ZBM, the apparent 16 mass unit difference between the two compounds suggested that they could be new BLM analogues with disaccharides varying by one hydroxyl group. Production of ZBM, 6'-hydroxy-ZBM, as well as BLM analogues in SB9027 suggested that the biosynthetic machineries for both BLM and ZBM aglycones are functional, and inactivation of the latter could afford a platform for the engineered production of BLM analogues exclusively (Figure 3A).

Engineering the *S. flavoviridis* Recombinant Strain SB9026 That Produces BLM Z and 6'-Deoxy-BLM Z. The *zbmVIII* gene encodes the PKS that is responsible for the biosynthesis of the polyketide moiety of ZBM (Figures S1 and S2).²⁵ We first deleted a 3.7-kb *SbfI* internal fragment of *zbmVIII* in SB9001 to construct an in-frame $\Delta zbmVIII$ deletion mutant strain SB9025 (Figure S5). The in-frame deletion strategy was preferred to ensure that the SB9025 mutant strain abolishes ZBM aglycone biosynthesis but remains competent to support ZBM disaccharide biosynthesis. pBS54 was next introduced into SB9025 via conjugation to afford the recombinant strain SB9026. Fermentation of SB9026, together with SB9001, SB9025, and SB9027 as controls, was carried out under the optimized conditions for ZBM production¹³ (SI). HPLC analysis of the metabolites produced confirmed that SB9025 completely lost ZBM production (Figure 3C, panels I vs III) and that SB9026 produced only the two predicted BLM analogues (Figure 3C, panels II vs IV), the exact phenotype




Figure 3. Engineered production of BLM Z and 6'-deoxy-BLM Z and evaluation of their DNA cleavage activities in comparison with BLM A2 and ZBM. (A) Proposed pathways for BLM and ZBM sugar biosynthesis in *S. verticillus* and *S. flavoviridis*, respectively, and expression of the BLM biosynthetic gene cluster in the ZBM-producing SB9001 for the production of ZBM, 6'-hydroxy-ZBM, BLM Z, and 6'-deoxy-BLM Z by SB9027 and in the $\Delta zbmVIII$ mutant strain SB9025 for the production of BLM Z and 6'-deoxy-BLM Z by SB9026. (B) The pBS54 clone with a 120-kb insert from *S. verticillus* ATCC15003 that harbors the intact BLM biosynthetic gene cluster cloned into the two *Bam*HI sites, along with the apramycin resistance marker (*AmR*), *oriT*, and $\Phi C31$. (C) HPLC analysis of ZBM (●) production in SB9001, SB9025, and SB9027, 6'-hydroxy-ZBM (○) production in SB9027, and BLM Z (◇) and 6'-deoxy-BLM Z (◆)

Figure 3. continued

production in SB9026 and SB9027. (D) DNA cleavage activities of BLM Z and 6'-deoxy-BLM Z as observed in plasmid relaxation assays with pBluescript II SK(+) in comparison with BLM A2 and ZBM. Form I, supercoiled plasmid DNA; form II, open circular plasmid DNA; form III, linearized plasmid DNA; EC₅₀, effective concentration at 50% plasmid DNA relaxation. See Figure S7 for relative ratios of single-strand cleavage (Form II) and double-strand cleavage (Form III) of supercoiled plasmid DNA (Form I).

that would be expected when expressing the BLM cluster in a ZBM aglycone-null host such as SB9025 (Figure 3A). The two new BLM analogues were produced in approximately a 1:1 ratio (Figure 3C, panel IV), and under the optimized fermentation conditions, their titers were estimated to be ~10 mg/L each.

Isolation of the two new metabolites produced by SB9026 was carried out by following protocols described previously for BLMs and analogues^{13,21,23,24} (SI). In brief, the fermentation broth (12 L) was centrifuged, and the supernatant was collected and adjusted to pH 7.0. After sequential column chromatography on Amberlite IRC-50, Diaion HP-20, and Sephadex LH-20, followed by semipreparative HPLC on a C-18 column, the two new metabolites were purified as blue BLM•Cu²⁺ complexes, named BLM Z•Cu²⁺ (8.3 mg) and 6'-deoxy-BLM Z•Cu²⁺ (9.7 mg), respectively. Final treatment of the BLM•Cu²⁺ complexes with EDTA, followed by HPLC on a C-18 column, afforded Cu²⁺-free BLM Z (2.1 mg) and 6'-deoxy-BLM Z (2.3 mg) as white powders, respectively.

The structures of BLM Z, a new BLM analogue with the ZBM terminal amine moiety (Figure 1), and 6'-deoxy-BLM Z, a new BLM analogue with both the ZBM terminal amine moiety and the ZBM disaccharide (Figure 1), were elucidated by a combination of MS and ¹H and ¹³C NMR spectroscopic analyses, as well as by comparison to the ¹H and ¹³C NMR data of BLM A2^{21,23,24} and ZBM¹³ (SI, Figures S6, S13–S23 and Tables S1 and S2). Thus, HR-MALDI-MS analysis in positive mode of the Cu²⁺-free BLM Z yielded an [M + H]⁺ ion at *m/z* 1382.5274, establishing the molecular formula of BLM Z as C₅₃H₇₉N₁₉O₂₁S₂ (calculated for C₅₃H₇₉N₁₉O₂₁S₂ + H⁺, 1382.5212). Analysis of 1D and 2D NMR spectra of BLM Z, along with comparison to those of BLM A2, indicated the presence of structural moieties characteristic of the BLMs, including the metal-binding domain—the pyrimidoblastic acid subunit along with the adjacent hydroxyl histidine, the (2*S*,3*S*,4*R*)-4-amino-3-hydroxy-2-methylpentanoic acid subunit, the disaccharide moiety, and the bithiazol group.^{13,21,23,24} Apart from these moieties, immediately identifiable from the NMR spectroscopic data for BLM Z were resonances consistent with the ZBM terminal amine moiety, 3-aminopropionamide [δ_{C} 169.2 (s), 33.0 (t), and 36.9 (t); δ_{H} 3.82 (m) and 2.83 (t, *J* = 6.8 Hz)].¹³ BLM Z was finally determined to be a new BLM analogue featuring the ZBM terminal amine moiety, whose assignment was unambiguously established on the basis of the key HMBC correlations between H₂-37 [δ_{H} 3.82 (m)] and the two tertiary carbons C-39 [δ_{C} 169.2 (s)] and C-36 [δ_{C} 163.7 (s)]. This deduced structure was further confirmed by detailed analysis of 1D and 2D NMR spectra (Figure S6), which also enabled the full ¹H and ¹³C NMR spectroscopic assignments for BLM Z as summarized in Tables S1 and S2 (SI).

HR-MALDI-MS analysis in positive mode of Cu²⁺-free 6'-deoxy-BLM Z yielded an [M + H]⁺ ion at *m/z* 1366.5198, establishing the molecular formula of 6'-deoxy-BLM Z as C₅₃H₇₉N₁₉O₂₁S₂ (calculated for C₅₃H₇₉N₁₉O₂₀S₂ + H⁺, 1366.5263). The 16 mass unit decrease in comparison with BLM Z supported the assignment of this new metabolite as a deshydroxyl analogue of BLM Z. Detailed comparison of the ¹H and ¹³C NMR data of this metabolite with those of BLM Z led to the conclusion that the only difference was that the hydroxymethylene group [δ_{C} at 60.5 and δ_{H} at 3.57 (overlap) and 3.42 (dd, *J* = 11.8 and 5.5 Hz)] at C-6' of the disaccharide in BLM Z was replaced by a methyl group [δ_{C} at 14.7 and δ_{H} at 0.90 (d, *J* = 6.5 Hz)] in 6'-deoxy-BLM Z (Figure S6). Taken together, these analyses finally established the new metabolite as 6'-deoxy-BLM Z, whose full ¹H and ¹³C NMR spectroscopic assignments are summarized in Tables S1 and S2 (SI).

Evaluating the DNA Cleavage Activities of 6'-Hydroxy-ZBM, BLM Z, and 6'-Deoxy-BLM Z, in Comparison to ZBM and BLM A2. 6'-Hydroxy-ZBM, BLM Z, and 6'-deoxy-BLM Z were compared to ZBM and BLM A2 for their ability to cleave pBluescript II SK(+) supercoiled plasmid DNA in the presence of Fe²⁺ as described previously^{9,21,23} (SI). BLM-mediated single-strand cleavage initially results in the conversion of supercoiled plasmid DNA (form I) to open circular plasmid DNA (form II), and double-strand cleavage subsequently generates linearized plasmid DNA (form III) (Figures 2C, 3D, and S7). In this assay, ZBM was significantly more potent than BLM A2. ZBM at 0.1 μM resulted in nearly 50% plasmid relaxation, whereas 0.2 μM BLM A2 was required for the same amount of plasmid relaxation (Figures 2C and 3D). Replacing the ZBM disaccharide with the BLM disaccharide resulted in an approximately 2-fold reduction in DNA cleavage activity. This was evident when comparing 6'-hydroxy-ZBM with ZBM, which exhibited 50% plasmid relaxation at 0.2 μM and 0.1 μM , respectively (Figure 2C). This finding also suggested that the ZBM disaccharide may be superior to the BLM disaccharide in mediating DNA cleavage. BLM Z and BLM A2 showed almost identical DNA cleavage activity, with 50% plasmid relaxation at 0.2 μM each (Figure 3D). The ZBM terminal amine moiety showed no significant difference in mediating DNA cleavage activity from the terminal amine moiety of BLM A2. The 6'-deoxy-BLM Z was most potent compound tested, exhibiting almost 100% plasmid relaxation at 0.1 μM , whereas 100% plasmid relaxation would require BLM A2, BLM Z, or ZBM minimally at 0.5 μM each (Figure 3D). This finding supports the previous data obtained with 6'-hydroxy-ZBM (Figure 2C) and allows us to conclude that the ZBM disaccharide is preferred and could be exploited to engineer BLM analogues with improved DNA cleavage activity (Figures 2 and 3).

The observed DNA cleavage activity was concentration-dependent for all of the BLMs and ZBMs tested. To determine the relative DNA cleavage activities of 6'-hydroxy-ZBM, BLM Z, and 6'-deoxy-BLM Z, in comparison with ZBM and BLM A2, the effective concentrations at 50% plasmid DNA relaxation (EC₅₀) were determined using 0.65 μg of pBluescript SK II (+) plasmid DNA, 10 μM Fe²⁺, and varying concentrations of 6'-hydroxy-ZBM (from 0.025 to 3.00 μM), BLM Z (from 0.010 to 1.00 μM), 6'-deoxy-BLM Z (from 0.010 to 1.00 μM), ZBM (from 0.02 to 2.00 μM), and BLM A2 (from 0.05 to 1.00 μM). Reactions were incubated at 37 °C for 30 min (Figure S7) (SI). The EC₅₀ values were estimated to be 0.26 ± 0.05 μM for 6'-hydroxy-ZBM, 0.22 ± 0.02 μM for BLM Z, 0.030 ± 0.003 μM

for 6'-deoxy-BLM Z, $0.10 \pm 0.01 \mu\text{M}$ for ZBM, and $0.32 \pm 0.02 \mu\text{M}$ for BLM A2 as summarized in Figures 2C and 3D. Again, 6'-deoxy-BLM Z exhibited an EC_{50} that was at least 10-fold more potent than BLM A2, representing the most potent BLM analogue known to date.^{1-4,8-13,21,24}

DISCUSSION

BLMs and TLMs differ from ZBM in their disaccharide moieties (Figure 1). Comparative analysis of the BLM, TLM, and ZBM biosynthetic machinery revealed that the L-gulose moiety in BLM resulted from direct epimerization of the NDP-D-mannose precursor by BlmG, while the combined action of ZbmL and ZbmG converted the NDP-D-mannose precursor into the 6-deoxy-L-gulose moiety found in ZBM (Figure S2).¹² The fact that ZBM production was abolished in the ΔzbmL mutant strain SB9003 and could be restored upon expression of a functional copy of *zbmL* in trans in recombinant strain SB9009 suggested that ZbmG and BlmG, in spite of their high sequence homology (64% identity/71% similarity), apparently exhibit distinct substrate specificity, ZbmG for NDP-4-keto-6-deoxy-D-mannose, and BlmG for NDP-D-mannose (Figures 2 and 3).^{12,16,25} ZbmL/ZbmG and BlmG therefore represent ideal candidates to use for engineering designer ZBM and BLM analogues with altered disaccharide moieties, on the assumption that the BlmEF or ZbmEF glycosyltransferases in both BLM and ZBM machineries are forgiving in the choice of the disaccharides to be incorporated into the BLM and ZBM aglycones (Figures 2A, 3A, and S2).

We took advantage of the expedient genetic system developed for *S. flavoviridis*²⁵ to investigate if novel ZBM analogues could be produced by cross-complementation of the ΔzbmL mutant strain SB9003 with *blmGEF* (as in SB9012), *blmGF* (as in SB9011), or *blmG* (as in SB9013) (Figure 2A). It was rather unexpected that the three recombinant strains afforded the same phenotype (Figure 2B), producing the same new ZBM analogue, which was subsequently characterized as 6'-hydroxy-ZBM featuring the BLM disaccharide (Figure 1). These findings confirmed that BlmG can functionally reconstitute NDP-L-gulose biosynthesis in the ΔzbmL mutant strain SB9003 and that the ZbmEF glycosyltransferase apparently can efficiently incorporate the altered sugar into the designer ZBM analogue. SB9011, SB9012, and SB9013 produced 6'-hydroxy-ZBM in a similar titer ($\sim 4 \text{ mg/L}$), which was approximately 40% of that of ZBM ($\sim 10 \text{ mg/L}$) by SB9003.¹³ The structure of 6'-hydroxy-ZBM was established on the basis of extensive MS and NMR spectroscopic data analyses (Figures S3, S8–S12 and Tables S1, S2).

Engineering sugar biosynthetic pathways for BLM in *S. verticillus*²¹ and for TLM in *S. hindustanus*²²⁻²⁴ have all been demonstrated, respectively, resulting in the production of BLM or TLM analogues with altered sugar moieties. We therefore attempted to carry out the reciprocal experiments in the BLM producer *S. verticillus*, by cross-complementing a ΔblmG mutant with *zbmLG*, to engineer a BLM analogue with the ZBM disaccharide. This approach was eventually abandoned due to the inability to effectively manipulate *S. verticillus* genetically.

We opted to express the entire BLM biosynthetic machinery in the ZBM producer *S. flavoviridis* to explore the feasibility of engineering novel BLM analogues in a genetically amenable heterologous host (Figure 3A).^{12,25} The recently developed *E. coli-Streptomyces* BAC shuttle vector²⁶ enabled us to construct a BAC (pBS54) that contained the entire BLM cluster on a 120-

kb insert (Figure 3B). The BAC pBS54 was introduced into *Streptomyces* heterologous hosts by *oriT*-mediated intergeneric conjugation and incorporated into chromosomes of the hosts via site-specific integration.²⁶⁻²⁸ Upon introduction of pBS54 into *S. flavoviridis* SB9001, the resultant recombinant strain SB9027 produced four major metabolites (Figure 3C, panel II). As expected, BLM Z and ZBM were produced, confirming functional expression of the BLM machinery from the introduced BAC clone pBS54 and of the ZBM machinery from the host background SB9001 under the conditions examined. However, two new hybrid metabolites, 6'-deoxy-BLM Z, a BLM analogue with the ZBM disaccharide and 6'-hydroxy-ZBM, a ZBM analogue with the BLM disaccharide were also produced. The production of 6'-deoxy-BLM Z and 6'-hydroxy-ZBM confirmed functional cross-talk between the biosynthetic machineries for the BLM and ZBM aglycones and their respective disaccharide moieties in the recombinant strain SB9027 (Figure 3A).¹²

We next constructed the $\Delta\text{zbmVIII}$ PKS mutant strain SB9025 in order to abolish the biosynthesis of the ZBM aglycone and create a cleaner background in the host so that the production of the BLM analogues, upon expression of the BLM biosynthetic machinery from pBS54, could be more readily discerned (Figure 3A). Introduction of pBS54 into the $\Delta\text{zbmVIII}$ PKS mutant strain SB9025 afforded recombinant strain SB9026, fermentation of which under the optimized conditions for ZBM production indeed produced only the two BLM analogues (Figure 3C, panel IV), each of which carried the BLM and ZBM disaccharide, respectively. SB9026 produced BLM Z and 6'-deoxy-BLM Z in approximately a 1:1 ratio with a titer of $\sim 10 \text{ mg/L}$ for each of the metabolites, which was comparable to that of ZBM levels ($\sim 10 \text{ mg/L}$) in the parent SB9001 strain.¹³ The structures of BLM Z and 6'-deoxy-BLM Z were established on the basis of extensive MS and NMR spectroscopic data analyses (Figures S6, S19–S23 and Tables S1, S2).

The anticancer activity of the BLM family of metabolites has been correlated with their in vitro DNA cleavage activity.^{1-4,8,9,21,23} Evaluation of the in vitro DNA cleavage activity of 6'-hydroxy-ZBM, BLM Z, and 6'-deoxy-BLM Z, compared to ZBM and BLM A2 as controls, shows the remarkable impact of the disaccharide on the activity of BLMs and ZBMs (Figures 2C, 3D, and S7). Among the over 160 BLM analogues that have been prepared and analyzed to date, none has shown much improvement in activity over the parent BLMs and very few have modifications at the disaccharide moiety.^{1-4,8-13,21,24} Although PLM and ZBM are known to be significantly more potent than the BLMs in mediating DNA cleavage, the BLMs are the only members of this family that have been developed into clinical drugs.¹⁻⁴ We now show that the ZBM disaccharide contributes, at least in part, to the superior activity of ZBM in mediating DNA cleavage and that the designer BLM analogue 6'-deoxy-BLM Z, which features the ZBM disaccharide, exhibits outstanding DNA cleavage activity in vitro. This was evidenced by its impressive EC_{50} of $0.030 \pm 0.003 \mu\text{M}$, which is approximately 1 order of magnitude smaller than BLM Z with an EC_{50} of $0.22 \pm 0.02 \mu\text{M}$ and BLM A2 with an EC_{50} of $0.32 \pm 0.02 \mu\text{M}$ under the conditions examined (Figures 2C, 3D, and S7). To the best of our knowledge, 6'-deoxy-BLM Z represents the most potent BLM known to date.^{1-4,8-13,21,24} Most importantly, these findings should inspire further effort toward creating additional analogues of BLM, specifically targeting the disaccharide moiety of BLM and screening for

even further improved activity. Emerging technologies in “glycorandomization” for natural product structural diversity should greatly facilitate such an endeavor.³⁰

It has been proposed that the dose-limiting, accumulative lung toxicity associated with BLM chemotherapy is independent of the cytotoxicity of BLMs to tumor cells.^{2,5–7} It has yet to be confirmed by in vivo study that the improved DNA cleavage activity observed in vitro with 6'-deoxy-BLM can be translated into improved anticancer activity with decreased side effects. Still, it is exciting to speculate that the increased potency of 6'-deoxy-BLM could have a great chance to result in new BLM chemotherapy regimens with a reduced dosage, thereby lessening the dose-limiting side effect and the incidence of lung toxicity.^{5–7} The fact that the 6'-deoxy-BLM is biosynthesized by the recombinant *S. flavoviridis* strain SB9026 and can be produced in reasonable quantities by scale-up microbial fermentation should greatly facilitate the follow-up mechanistic and preclinical studies as well as its development into a potential clinical drug.

Abbreviations. BAC, bacterial artificial chromosome; BLM, bleomycin; CID; collision-induced dissociation; ESI, electrospray ionization; HR, high resolution; MALDI, matrix-assisted laser desorption ionization; MS, mass spectrometry; NRPS, nonribosomal peptide synthetase; PKS, polyketide synthase; PLM, phleomycin; SI, supporting information; TLM, tallysomyacin; ZBM, zorbamycin.

■ ASSOCIATED CONTENT

● Supporting Information

A complete description of materials, methods, and detailed experimental procedures. Also included in SI are: (i) Figures S1 and S2 depicting the BLM, TLM, and ZBM biosynthetic gene clusters and the proposed pathways for BLM, TLM, and ZBM sugar biosynthesis and attachment to their respective aglycones; (ii) Tables S1 and S2 summarizing ¹H and ¹³C NMR data of ZBM, 6'-hydroxy-ZBM, BLM Z, and 6'-deoxy-BLM Z; (iii) Figures S3 and S8–S12 of ¹H, ¹³C, ¹H–¹H gCOSY, gHMBC, and gHMBC NMR spectra of 6'-hydroxy-ZBM; (iv) Figure 4 summarizing the failed attempt to produce BLMs in SB9028, SB9029, and SB9030; (v) Figure S5 depicting the construction of the $\Delta zbmVIII$ mutant strain SB9025 and confirmation of its genotype by Southern analysis; (vi) Figures S6 and S13–S18 of ¹H, ¹³C, ¹H–¹H gCOSY, gHMBC, gHSQC, and HSQC-TOCSY NMR spectra of BLM Z; (vii) Figures S6 and S19–S23 of ¹H, ¹³C, ¹H–¹H gCOSY, gHMBC, and gHMBC NMR spectra of 6'-deoxy-BLM Z; and (viii) Figure S7 summarizing DNA cleavage activities of 6'-hydroxy-ZBM, BLM Z, and 6'-deoxy-BLM Z in comparison with BLM A2 and ZBM as observed in plasmid relaxation assays with pBluescript II SK(+). This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

shenb@scripps.edu; ywduan66@yahoo.com.

Author Contributions

#These authors contributed equally.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank Dr. Marie F. Coeffet-LeGal, Cubist Pharmaceuticals Inc., Lexington, MA 02421, for providing the pStreptoBAC V vector, the Analytical Instrumentation Center of the School of Pharmacy, UW-Madison for support in obtaining MS and NMR data, and the John Innes Center, Norwich, U.K., for providing the REDIRECT Technology kit. This work was supported in part by the Chinese Ministry of Education 111 Project B08034 (to Y.D.) and the NIH grant CA94426 (to B.S.).

■ REFERENCES

- (1) Boger, D. L.; Cai, H. *Angew. Chem., Int. Ed.* **1999**, *38*, 448–476.
- (2) Hecht, S. M. *J. Nat. Prod.* **2000**, *63*, 158–168.
- (3) Chen, J.; Stubbe, J. *Nat. Rev. Cancer* **2005**, *5*, 102–112.
- (4) Galm, U.; Hager, M. H.; Van Lanen, S. G.; Ju, H.; Thorson, J. S.; Shen, B. *Chem. Rev.* **2005**, *105*, 739–758.
- (5) Einhorn, L. H. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 4592–4595.
- (6) Huddart, R. A.; Birtle, A. J. *Exper. Rev. Anticancer Ther.* **2005**, *5*, 123–138.
- (7) Sleijfer, S. *Chest* **2001**, *120*, 617–624.
- (8) Leitheiser, C. J.; Smith, K. L.; Rishel, M. J.; Hashimoto, S.; Konishi, K.; Thomas, C. J.; Li, C.; McCormick, M. M.; Hecht, S. M. *J. Am. Chem. Soc.* **2003**, *125*, 8218–8227.
- (9) Ma, Q.; Xu, Z.; Schroeder, B. R.; Sun, W.; Wei, F.; Hashimoto, S.; Konishi, K.; Leitheiser, C. J.; Hecht, S. M. *J. Am. Chem. Soc.* **2007**, *129*, 12439–12452.
- (10) Chapuis, J.-C.; Schmaltz, R. M.; Tsosie, K. S.; Belohlavek, M.; Hecht, S. M. *J. Am. Chem. Soc.* **2009**, *131*, 2438–2439.
- (11) Takita, T.; Muraoka, Y. In *Biochemistry of Peptide Antibiotics: Recent Advances in the Biotechnology of β -Lactam and Microbial Peptides*; Kleinkauf, H.; von Dohren, H., Eds.; W de Gruyter: New York, 1990; pp 289–309.
- (12) Galm, U.; Wendt-Pienkowski, E.; Wang, L.; Huang, S.-X.; Unsin, C.; Tao, M.; Coughlin, J. M.; Shen, B. *J. Nat. Prod.* **2011**, *74*, 526–536.
- (13) Wang, L.; Yun, B.-S.; George, N. P.; Wendt-Pienkowski, E.; Galm, U.; Oh, T.-J.; Coughlin, J. M.; Zhang, G.; Tao, M.; Shen, B. *J. Nat. Prod.* **2007**, *70*, 402–406.
- (14) Van Lanen, S. G.; Shen, B. In *Antitumor Agents from Natural Products*, 2nd ed.; Kingston, D. G. I., Cragg, G. M., Newman, D. J., Eds.; CRC Press: Boca Raton, FL, 2012; pp 667–694.
- (15) Du, L.; Shen, B. *Chem. Biol.* **1999**, *6*, 507–517.
- (16) Du, L.; Sanchez, C.; Chen, M.; Edwards, D. J.; Shen, B. *Chem. Biol.* **2000**, *7*, 623–642.
- (17) Du, L.; Chen, M.; Sanchez, C.; Shen, B. *FEMS Microbiol. Lett.* **2000**, *189*, 171–175.
- (18) Sanchez, C.; Du, L.; Edwards, D. J.; Toney, M. D.; Shen, B. *Chem. Biol.* **2001**, *8*, 725–738.
- (19) Schneider, T. L.; Shen, B.; Walsh, C. T. *Biochemistry* **2003**, *42*, 9722–9730.
- (20) Du, L.; Chen, M.; Zhang, Y.; Shen, B. *Biochemistry* **2003**, *42*, 9731–9740.
- (21) Galm, U.; Wang, L.; Wendt-Pienkowski, E.; Tao, M.; Coughlin, J. M.; Shen, B. *J. Biol. Chem.* **2008**, *283*, 28236–28245.
- (22) Tao, M.; Wang, L.; Wendt-Pienkowski, E.; George, N. P.; Galm, U.; Zhang, G.; Coughlin, J. M.; Shen, B. *Mol. Biosyst.* **2007**, *3*, 60–74.
- (23) Wang, L.; Tao, M.; Wendt-Pienkowski, E.; Galm, U.; Coughlin, J. M.; Shen, B. *J. Biol. Chem.* **2009**, *284*, 8256–8264.
- (24) Tao, M.; Wang, L.; Wendt-Pienkowski, E.; Zhang, N.; Yang, D.; Galm, U.; Coughlin, J. M.; Xu, Z.; Shen, B. *Mol. Biosyst.* **2010**, *6*, 349–356.
- (25) Galm, U.; Wendt-Pienkowski, E.; Wang, L.; George, N. P.; Oh, T.-J.; Yi, F.; Tao, M.; Coughlin, J. M.; Shen, B. *Mol. Biosyst.* **2009**, *4*, 77–90.

- (26) Miao, V.; Coeffet-LeGal, M. F.; Brian, P.; Brost, R.; Penn, J.; Whiting, A.; Martin, S.; Ford, R.; Parr, I.; Bouchard, M.; Silva, C. J.; Wrigley, S. K.; Baltz, R. H. *Microbiology* **2005**, *151*, 1507–1523.
- (27) Feng, Z.; Wang, L.; Rajski, S. R.; Xu, Z.; Coeffet-LeGal, M. F.; Shen, B. *Bioorg. Med. Chem.* **2009**, *17*, 2147–2153.
- (28) Yang, D.; Zhu, X.; Wu, X.; Feng, Z.; Huang, L.; Shen, B.; Xu, Z. *Appl. Microbiol. Biotechnol.* **2011**, *89*, 1709–1719.
- (29) Galm, U.; Shen, B. *Expert Opin. Drug Discovery* **2006**, *1*, 409–437.
- (30) Gantt, R. W.; Peltier-Pain, P.; Thorson, J. S. *Nat. Prod. Rep.* **2011**, *28*, 1811–1853.